High-dose therapy and autologous stem cell transplantation for extra-nodal NK/T lymphoma in patients from the Western hemisphere

• Verfasst von: Fox, Christopher [VerfasserIn]
• Verfasst von: Dreger, Peter [VerfasserIn]
• Titel: High-dose therapy and autologous stem cell transplantation for extra-nodal NK/T lymphoma in patients from the Western hemisphere
• Titelzusatz: a study from the European Society for Blood and Marrow Transplantation
• Verf.angabe: Christopher P. Fox, Ariane Boumendil, Norbert Schmitz, Herve Finel, Jian J. Luan, Gülsan Sucak, Didier Blaise, Jürgen Finke, Karl-Heinz Pflüger, Hendrik Veelken, Norbert -Claude Gorin, Xavier Poiré, Arnold Ganser, Peter Dreger, Anna Sureda
• E-Jahr: 2015
• Jahr: 26 Aug 2015
• Umfang: 6 S.
• Teil: volume:56
• Teil: year:2015
• Teil: number:12
• Teil: pages:3295-3300
• Teil: extent:6
• Fussnoten: Gesehen am 05.08.2021
• Titel Quelle: Enthalten in: Leukemia and lymphoma
• Ort Quelle: London [u.a.] : Taylor & Francis Group, 1989
• Jahr Quelle: 2015
• Band/Heft Quelle: 56(2015), 12, Seite 3295-3300
• ISSN Quelle: 1029-2403
• DOI: doi:10.3109/10428194.2015.1037764
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: Epstein-Barr virus
• Sach-SW: high-dose therapy
• Sach-SW: natural killer cell lymphoma
• Sach-SW: stem cell transplantation
• K10plus-PPN: 176562827X

Abstract

Extra-nodal NK/T lymphoma (ENKTL) is rare and more frequently encountered in East Asia. The role of high-dose therapy and autologous stem cell transplantation (HDT-ASCT) for ENKTL is unclear. Twenty-eight evaluable patients who had undergone HDT-ASCT in Europe from 2000-2009 were studied. The median age was 47 years and patients had received a median of two lines of prior therapy. Some 57% of patients were not in complete remission or beyond first complete remission at HDT-ASCT. The 1-year non-relapse mortality (NRM) was 11%; 2-year progression-free survival (PFS) and overall survival (OS) rates were 41% and 52%, respectively. Notably, the 2-year PFS and OS for those with stage III/IV disease were 33% and 40%, respectively, with no relapses beyond 1-year post-HDT-ASCT. This is the largest analysis of HDT-ASCT for patients with ENKTL reported from the Western hemisphere. Survival is comparable to East Asian cohorts and outcomes are encouraging for patients with advanced disease.